with Audrey Turley, B.S., RM (NRCM), CBA (ASQ)

Slides:



Advertisements
Similar presentations
On the relationship between ISO/DTS29321 and ISO14971 & Japans Comments for new draft & amended clause 8 final of ISO/DTS /5/2008 JAHIS.
Advertisements

1 Managing Authority Conducting a self assessment 10 June 2008 A. Badrichani – DG Regional Policy – Audit Unit J3.
Protocol Development.
Introduction to Integrated Library Systems
Dissertation Writing.
Presented by: Nick McHugh Date: 15/11/2005 Security, Safety, Confidence.
Avoiding Pitfalls: Testing Considerations
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH Working with FDA: Biological Products and Clinical Development Critical Path.
6/23/2015 Risk-Informed Process and Tools for Permitting Hydrogen Fueling Stations Jeffrey LaChance 1, Andrei Tchouvelev 2, and Jim Ohi 3 1 Sandia National.
Learning Outcomes from Report-Writing Unit
Prepared for the Ottawa Region MISA Professional Network Centre - Summer 2006 Writing a Research Proposal for Funding An Overview.
Food and Drug Administration Center for Biologics Evaluation and Research The Office of Cellular, Tissue and Gene Therapies Web Seminar Series presents:
Putting the Pieces Together…. Understanding SLOs.
Introduction to ISO New and modified requirements.
Literature Review and Parts of Proposal
International Atomic Energy Agency Code of Conduct on the Safety and Security of Radioactive Sources Training Course on Technical Requirements to Fulfill.
Slide 1 of 22 Rob Packard, President 510(k) Project Management.
ICH V1 An FDA Update Min Chen, M.S., RPh Office of Drug Safety Center for Drug Evaluation and Research FDA January 21, 2003.
Setting up an Internal Audit Program By
March 28, 2006 Combination Products: Preparing for the Journey March 28, 2006 Pamela J. Weagraff Principal Consultant.
Kimberly A. Trautman FDA’s Medical Device Quality System Expert
510(k) Submissions Recent Experience and Perspectives Terry Sullivan Vice President, Regulatory Affairs.
Leukocyte-Reduced Blood Components Lore Fields MT(ASCP)SBB Consumer Safety Officer, DBA, OBRR, CBER September 16, 2009.
IAEA International Atomic Energy Agency Summary and Overview of TECDOC Russel Edge Decommissioning and Remediation Unit Division of Radiation,Transport.
Overview of FDA's Regulatory Framework for PET Drugs
 Definition of a quality Audit  Types of audit  Qualifications of quality auditors  The audit process.
Project Proposal. What is Project Proposal?  A project proposal is written, to make an offer and to try to convince a supervisor or a future customer.
IAEA International Atomic Energy Agency Methodology and Responsibilities for Periodic Safety Review for Research Reactors William Kennedy Research Reactor.
International Atomic Energy Agency Regulatory Review of Safety Cases for Radioactive Waste Disposal Facilities David G Bennett 7 April 2014.
IAEA International Atomic Energy Agency Development of the Basis Document for Periodic Safety Review for Research Reactors William Kennedy Research Reactor.
6/11/04Part 11 Public Meeting1 Risk-Based Approach Scott M Revolinski Washington Safety Management Solutions Carolyn Apperson-Hansen Cleveland Clinic Foundation.
Regulation of Medical Devices: Tanzania experience Fimbo, A. M Tanzania Food and Drugs Authority.
Best Practices in CMSD SLO Development A professional learning module for SLO developers and reviewers Copyright © 2015 American Institutes for Research.
Workshop on Accreditation of Bodies Certifying Medical Devices Kiev, November 2014.
Quality Management Systems Advice from ISO/TC 176 for Sector-specific applications.
WORK EXPERIENCE INDEPENDENT PLACEMENTS. Who are we? We are an independent charity that has been organising work related learning activity since 1993 We.
Family Assessment Service Engagement Event 21 st August 2013 NWCE-9A3GPK.
2016/06/211 Provision of Civil Works at Simmerpan Substation PS(PDP)2015/FM/15 Date : 10 July 2015.
Auditing ISO Nancy Pasquan November Introductions I am….. You are….. And we are here to discuss: Auditing ISO Quality Systems for Medical.
Performance-Based Accreditation
Welcome to the FSSC Global Markets Webinar 11 September 2017, 4pm CET
FDA's Two New Draft Guidance on Software and Device
Strengthening the Medical Device Clinical Trial Enterprise
Deliverables, final review and final reporting
Communication: Safety Summary
GD211 Training Module 5 Conclusions.
IAEA E-learning Program
VenaSeal Closure System Utilization of the Pre-Submission Process & Interactive Review Sponsor’s Perspective 24 February 2015.
Pre-Investigational New Drug (pre-IND) Meeting with FDA
CTD Content Management
Writing Skills Application Materials Workshop Hiring Committee Reports.
Prepared by Rand E Winters, Jr. ASR Senior Auditor October 2014
Formal Meetings between FDA and Sponsors of PDUFA Products
FDA Guidance for Industry and FDA Staff Summary of Public Notification of Emerging Postmarket Medical Device Signals (“Emerging Signals”) Effective: December.
ISO 9001:2015 Auditor / Registration Decision Lessons Learned
Cuero ISD Education Foundation
QPS EVALUATION SERVICES INC.
Setting up an Internal Audit Program
Reporting to the CPHS: Unanticipated Problems & Serious Adverse Events
PEST Committee Comments
Introduction to ISO 9000 ISO
Linda M. Chatwin, Esq. RAC Business Manager, UL LLC
PRI Registrar November 2, 2018
United Nations Voluntary Fund on Disability (UNVFD)
Joint BES/BBS Seminar Patient Preference Studies – Introduction
Understanding Standards Graphic Communication Advanced Higher
Overview of the recommendations on software updates
ISO and TR Update for FDA Regulated Industries
FDA Center for Biologics Evaluation and Research (CBER) INitial Targeted Engagement for Regulatory Advice on CBER producTs (INTERACT) Meetings *Audio.
Introduction to Extended Reflection 1 Term 1, Development Day 1
Presentation transcript:

with Audrey Turley, B.S., RM (NRCM), CBA (ASQ) How to Develop a Risk Based Biological Safety Evaluation Per New US FDA Guidance Day 3: Summarize all your findings in a Biological Evaluation Report (BER) with Audrey Turley, B.S., RM (NRCM), CBA (ASQ) Research Scientist

BIOLOGICAL SAFETY EVALUATION BEP: What are your risks and how do you plan to mitigate them? Testing and risk assessments BER: Is the device safe?

WEBINAR SUMMARY DAY 1 – Biological Evaluation Plan (BEP) Assessing your biocompatibility is not a checklist approach! Send BEP to regulatory bodies BEFORE you begin.

WEBINAR SUMMARY DAY 2 – Understanding Test Options Know your material, perform useful E&L testing and follow up with a risk assessment. ISO 10993-1:2009 - Figure 1

STANDARDS FOR PRESENTATION ISO 10993-1: 2009 “Biological evaluation of medical devices – Part 1: Evaluation and testing within a risk management process”. US FDA guidance document “Use of International Standard ISO 10993-1, ‘Biological evaluation of medical devices - Part 1: Evaluation and testing within a risk management process’” issued June 16, 2016.

STANDARDS FOR PRESENTATION Agency advises to start using this now as most submissions will not be complete before the effective date of September 14, 2016. The link to the document is here.

What is a Biological Evaluation Report? ANSWER A BER is a summary of all the evidence gathered to support the biological safety of a device. Requested in US FDA guidance document ISO 10993-1 Clause 7 and Annex B

Why do I need a BER? 3) BER If conclusion = “device is safe”, then 1) BEP 2) Testing/risk assessments

Why can’t I just submit all my testing reports? Implant device Predicate device E&L testing Tox Risk Assessment Cytotoxicity, irritation, sensitization Particulate testing Biological Risk Assessment

What should a BER contain? ISO 10993-1 clause 7: “Interpretation of biological evaluation data and overall biological safety assessment” a) “the strategy and program content for the biological evaluation of the medical device;” BEP b) “the criteria for determining the acceptability of the material for the intended purpose, in line with the risk management plan;” Internal documentation from R&D

What should a BER contain? c) “the adequacy of the material characterization;” If used to justify out of testing Well characterized material Novel material/process

What should a BER contain? d) “the rationale for selection and/or waiving of tests;” BEP e) “the interpretation of existing data and results of testing;” Address any unusual findings

What should a BER contain? f) “the need for any additional data to complete the biological evaluation;” Extended evaluations, change in standards, etc. g) “overall biological safety conclusions for the medical device.” Have all the risks been mitigated?

Can I Write a BER myself? Yes Ensure that all the points in clause 7 are included. FDA guidance document, Attachment C

Summary of 7 points (a-g) a) Strategy to assess device. What was the BEP? b) Justification for materials used c) Was the material characterization adequate? d) Rationale for selection/waiving of tests e) Data review and interpretation f) Was everything covered? g) Is the device safety well supported?

Can I Write the BER myself? A few things to keep in mind… ISO 10993-1 states that “Expert assessors..” should review the findings and make an overall conclusion. Outside perspective Help with the submission process if it comes back

What does Nelson offer in a BER? BACKGROUND Reason for testing Device Company a) Strategy to assess device. What was the BEP?

What does Nelson offer in a BER? DEVICE DESCRIPTION What is it used for Where in the body is it used Target population b) Justification for materials used

What does Nelson offer in a BER? a) Strategy to assess device. What was the BEP? d) Rationale for selection/waiving of tests DEVICE CATEGORIZATION ISO 10993-1:2009 Device contact Biological considerations Duration

What does Nelson offer in a BER? COMPONENTS AND MATERIALS Material biocompatibility data COAs Suppliers b) Justification for materials used

What does Nelson offer in a BER? TESTING SUMMARY Tests performed Laboratory Standards followed Study numbers Results Abnormal results c) Was the material characterization adequate? e) Data review and interpretation f) Was everything covered?

What does Nelson offer in a BER? c) Was the material characterization adequate? e) Data review and interpretation f) Was everything covered? RISK ASSESSMENT DISCUSSION Biological Risk Toxicological Risk

What does Nelson offer in a BER? CONCLUSION The device is considered biocompatible. The device is safe for only the following populations… There are remaining areas of risk that need to be addressed. g) Is the device safety well supported?

What if… …I didn’t have a BEP? … the testing was done over several years? …the device has gone through several design changes since the testing? …we’re putting this all together as an afterthought?

Example Projects Catheter family Latex gloves List all components and justify the use of a representative sample Latex gloves Failing cytotoxicity results Kit with several components purchased at separate facilities Failing cyto results on one component New catheter Predicate device from same manufacturer but shorter in length

BIOLOGICAL SAFETY EVALUATION BEP: What are your risks and how do you plan to mitigate them? Testing and risk assessments BER: Is the device safe?

Thank you for attending Questions? Thank you for attending How to Develop a Risk Based Biological Safety Evaluation Per New US FDA Guidance